EU Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) vs Horizon 2020. However MEPs said that the new moonshot research section EIC is underfunded. Furthermore, the current funding quote of 11% was too low compared to other international excellence programmes.
https://european-biotechnology.com/wp-content/uploads/2024/04/EC_Horizon_Europe_P037339-40482.jpg12801920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-08 08:08:522018-06-08 08:08:52EC earmarks €100bn for Horizon Europe
Alkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes’ relapsing-remitting multiple sclerosis candidate diroximel fumarate (BIIB098).
Austrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
PureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_Leiden.jpg303303h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-05 15:15:452018-06-05 15:15:45PureTech’s Gelesis Appoints Harry Leider as CMO
The US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the label.
https://european-biotechnology.com/wp-content/uploads/2024/04/Emicizumab_MoA__2_.png18885529Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-05 08:04:252018-06-05 08:04:25Roche set to extend Hemlibra label
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 2018 meeting.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-04 05:57:122018-06-04 05:57:12EMA recommends nine drugs for approval
Despite seemingly insurmountable environmental challenges ahead and the many successes’ flaunted by big biorefinery projects, the wider business community remains stubbornly sceptical about developing business within the bio-based paradigm. Now policymakers are pushing financiers to take a bigger stake in its success. New efforts are underway to drive private investment in bioeconomy ventures.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2018_spring_bioeconomy.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-03 05:08:002024-04-02 16:21:21Follow the money – from niche to norm
Sygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the company’s international growth plans.
https://european-biotechnology.com/wp-content/uploads/2024/04/Eb_online_appointments_sygnature.JPG700700h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-01 15:59:562018-06-01 15:59:56Sygnature Discovery appoints Dr Bill Marathias
EC earmarks €100bn for Horizon Europe
Latest NewsEU Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) vs Horizon 2020. However MEPs said that the new moonshot research section EIC is underfunded. Furthermore, the current funding quote of 11% was too low compared to other international excellence programmes.
Josh Muntner joins Mesoblast as CFO
AppointmentsJosh Muntner has been appointed Chief Financial Officer of Mesoblast. He will be based in New York.
MS: Alkermes bags US$50m milestone from Biogen
Latest NewsAlkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes’ relapsing-remitting multiple sclerosis candidate diroximel fumarate (BIIB098).
Hookipa and Gilead ink US$400m deal
Latest NewsAustrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
PureTech’s Gelesis Appoints Harry Leider as CMO
AppointmentsPureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.
Roche set to extend Hemlibra label
Latest NewsThe US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the label.
Hikma appoints Henriette Nielsen
AppointmentsHikma Pharmaceuticals PLC announces the appointment of Henriette Nielsen to the newly created role of Chief Transformation Officer.
EMA recommends nine drugs for approval
Latest NewsThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 2018 meeting.
Follow the money – from niche to norm
BackgroundDespite seemingly insurmountable environmental challenges ahead and the many successes’ flaunted by big biorefinery projects, the wider business community remains stubbornly sceptical about developing business within the bio-based paradigm. Now policymakers are pushing financiers to take a bigger stake in its success. New efforts are underway to drive private investment in bioeconomy ventures.
Sygnature Discovery appoints Dr Bill Marathias
AppointmentsSygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the company’s international growth plans.